Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - Amgen (Nasdaq:AMGN) today presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy ("the 103 study"). Aranesp is not approved for use by the FDA or EMEA in these patients. These results were presented in an oral session at the 2007 American Association for Cancer Research (AACR) annual meeting in Los Angeles, Calif. (AACR Abstract #LB-3).

As reported in January, the study did not meet its primary endpoint of reducing red blood cell (RBC) transfusions in the Aranesp treatment group. Transfusion occurrences from weeks 5 to 17 favored Aranesp but were not statistically significant between the groups (hazard ratio: 0.85, p=0.32). Among those receiving Aranesp, there was a significantly higher proportion of patients with a hemoglobin response (p less than 0.0001), hemoglobin correction (p less than 0.001), and hematopoietic response (p=0.002) compared with placebo.

The adverse event rate was similar between the groups. However, the overall number of deaths was greater in the Aranesp group (48.5 percent versus 46 percent in placebo; hazard ratio: 1.29; p=0.006). In post-hoc analyses adjusting for stratification factors at randomization and sex, stage IV disease, prior chemotherapy use and prior radiotherapy use, there remained a significant difference in survival between the groups. However, hazard ratios and statistical significance diminished when the analyses were further adjusted for known prognostic factors including baseline ECOG status, tumor type, tumor stage, baseline FACT-F cutoff at median and baseline Hb (hazard ratio: 1.17, p=0.11).

"This study evaluated ESA treatment for patients with active cancer, not receiving chemotherapy or radiation
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:2/26/2015)... Feb. 26, 2015 Legislation passed today by ... provision to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA) of 2014 , ... Kevin Brady (R-TX) and Ranking Member Jim McDermott ... abuse epidemic and implement the right policies, said the ...
(Date:2/26/2015)... February 26, 2015 LifeScienceIndustryResearch.com ... First -In- Class Innovations and Cost Optimization Plays ... Cap Pharmaceutical Companies research report to the pharmaceuticals ... to this Global Pharma US & EU Outlook ... measurements, divestment of non-core assets result in healthy ...
(Date:2/26/2015)...  BD Life Sciences, a segment of BD ... ), a leading global medical technology company, and ... high-resolution biology, today announced that they will be ... cell isolation and single-cell gene expression analysis. ... FACS™ single-cell sorting instrumentation and software with Cellular ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... SAN FRANCISCO, June 6 OxyBand Technologies Inc., ... the company,s bio-medical,technology development and expand the company,s ... for,health, cosmetic and consumer care. The company,s inaugural ... the FDA for medical and over the,counter marketing. ...
... Data Indicate Overall and Disease-Free Survival -, ... adjuvant trial in,high-risk melanoma patients demonstrated that a ... and/or overall,survival. These findings, which indicate Leukine,s potential ... annual meeting of the American Society,of Clinical Oncology ...
Cached Medicine Technology:OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5
(Date:2/27/2015)... MA (PRWEB) February 27, 2015 ... mobility management services, and one of the ... announced support for Bell Mobility within their CLEAN ... of services. Wireless Analytics’ newly developed Bell ... reporting for the Canadian wireless carrier’s business customers. ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... “cutters”, are often misunderstood, misdiagnosed and therefore ... to healthy lives. Jacksonville-based addiction treatment ... of its highly acclaimed Lakeview Professional Lecture ... interested in understanding this complicated condition. ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma ... Cancer Institute (NCI) will co-host the annual International ... of Health (NIH), in Bethesda, Maryland. The event ... medical professionals and scientists who specialize in mesothelioma, ... public, including patients, their families, and caregivers. , ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ... as their doc-link for Dynamics Partner of the Year. ... solutions for their customers in all different industries with ... and BPW have worked side-by-side to successfully help clients ... , “We are so impressed by the success that ...
Breaking Medicine News(10 mins):Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... ATS 2008, TORONTOXScientists believe they may have identified a ... risk of allergy and asthma in childhood. They will ... International Conference in Toronto on Tuesday, May 20., Several ... without allergy at the time of birth. For example, ...
... 21 The Quantum Group,Inc. (Amex: QGP, QGP.WSA, QGP.WSB) ... successfully completed a corporate expansion plan. The Company,increased its ... facility size from 6,600 sq. ft. to 10,600 sq. ... to a larger facility in Doral (west,Miami), Florida., ...
... 21 Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading ... ended March 31, 2008., Revenue in the quarter ... revenue of $9,806,540 and an increase of 31% over ... profit improved to,$2,310,854 in the first quarter of 2008, ...
... ACM today announced a new strategic,alignment that ... next generation technology and services to the two ... commercial plans and,payers, and federal and state governments., ... has been,named EVP/General Manager for Government, and will ...
... sleep apnea (OSA) in very young children may cause ... older children and adults with the condition, according to ... the American Thoracic Societys 2008 International Conference in Toronto ... year of life, said Aviv Goldbart, M.D., the pediatric ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
Cached Medicine News:Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Frontier Anterior Deformity System unites the ... Moss Miami, and Isola with revolutionary ... to deliver unsurpassed versatility, simplicity and ... level of versatility for treating a ...
Medicine Products: